Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study


Autoria(s): Santos, Petra dos; Zanetti, Juliana da Silva; Silva, Alfredo Ribeiro da; Beltrão, Eduardo IC
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

14/10/2013

14/10/2013

16/08/2012

Resumo

Abstract Background The main focus of several studies concerned with cancer progression and metastasis is to analyze the mechanisms that allow cancer cells to interact and quickly adapt with their environment. Integrins, a family of transmembrane glycoproteins, play a major role in invasive and metastatic processes. Integrins are involved in cell adhesion in both cell-extracellular matrix and cell-cell interactions, and particularly, β1 integrin is involved in proliferation and differentiation of cells in the development of epithelial tissues. This work aimed to investigate the putative role of β1 integrin expression on survival and metastasis in patients with breast invasive ductal carcinoma (IDC). In addition, we compared the expression of β1 integrin in patients with ductal carcinoma in situ (DCIS). Methods Through tissue microarray (TMA) slides containing 225 samples of IDC and 67 samples of DCIS, β1 integrin expression was related with several immunohistochemical markers and clinicopathologic features of prognostic significance. Results β1 integrin was overexpressed in 32.8% of IDC. In IDC, β1 integrin was related with HER-2 (p = 0.019) and VEGF (p = 0.011) expression and it had a significant relationship with metastasis and death (p = 0.001 and p = 0.05, respectively). Kaplan-Meier survival analysis showed that the overexpression of this protein is very significant (p = 0.002) in specific survival (number of months between diagnosis and death caused by the disease). There were no correlation between IDC and DCIS (p = 0.559) regarding β1 integrin expression. Conclusions Considering that the expression of β1 integrin in breast cancer remains controversial, specially its relation with survival of patients, our findings provide further evidence that β1 integrin can be a marker of poor prognosis in breast cancer. Virtual slides The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/6652215267393871

We thank CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico, Brazil) and FAPESP (Fundação de Amparo a Pesquisa do Estado de São Paulo, Brazil) for financial support, CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Brazil) and FACEPE (Fundação de Amparo à Ciência e Tecnologia do Estado de Pernambuco, Brazil) for schollarships and financial support; and Deisy Mara da Silva for technical assistance.

This research is in accordance with Declaration of Helsinki, and was aprooved by the local ethics comitee.

Identificador

DIAGNOSTIC PATHOLOGY, LONDON, v. 7, AUG 16, 2012

1746-1596

http://www.producao.usp.br/handle/BDPI/34857

http://dx.doi.org/10.1186/1746-1596-7-104

10.1186/1746-1596-7-104

http://www.diagnosticpathology.org/content/7/1/104

Idioma(s)

eng

Publicador

LONDON

Relação

Diagnostic Pathology

Direitos

openAccess

dos Santos et al.; licensee BioMed Central Ltd. - This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Palavras-Chave #BETA 1 INTEGRIN; TISSUE MICROARRAY; IMMUNOHISTOCHEMISTRY; PROGNOSIS;
Tipo

article